一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括QL1706 combined with Chemotherapy，当前状态为招募中。登记地点显示中国天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
QL1706 combined with Chemotherapy · II 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁至75 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Tianjin Medical University Cancer Institute & Hospital · 天津
公开的入选条件
- * Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- * Age: 18-75 years old (at the time of signing the informed consent form);
- * ECOG PS score: 0-1; expected survival time exceeding 6 months;
- * Patients with primary breast cancer confirmed by histopathological or cytological examination;
- * Primary tumor diameter \> 2 cm as measured by local standard assessment methods;
- * Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- * According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: I
- * At least one measurable lesion according to RECIST 1.1;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07372079；登记信息更新于 2026-09-28。